7月8日，SELLAS Life Sciences盘中上涨8.59%，报14.8美元/股，成交额2022.73万美元。
消息面上，公司核心产品Galinpepimut-S（GPS）针对急性髓系白血病（AML）的关键性三期REGAL试验已累计发生78例事件，距触发最终分析的80例仅差2例，数据读出预期持续升温。此外，该股近期成为Reddit社区Wallstreetbets热门标的，资金关注度显著提升，叠加逼空效应放大波动。基本面方面，公司Q1每股亏损0.05美元优于市场预期的0.06美元，期末现金储备达1.071亿美元，为后续临床推进提供充足保障。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.